All In Biotech

Drug Trial Radar · NCT06299098

A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation

A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,005 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,005

Actual

Start

Mar 13, 2024

Primary completion

Jun 16, 2026

Study completion Oct 21, 2026

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Mar 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (Wegovy®). This study will be done in 3 parts, Part A, Part B, and Part C where different study drugs will be tested. Part A of the study is focused on healthy participants. Part B and C of the study is focused on participants with obesity. The aim of Part A of the study is to see how safe and tolerable the study drug is in healthy participants. The aim of Part B and Part C of the study is to see how safe and effective the study drug is when combined with Wegovy. Parts A, B, and C of the study are looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Conditions

  • Obesity

Interventions

  • Trevogrumab-Part ADrug

    Administered IV or SC in Part A

  • Trevogrumab-Part B and Part CDrug

    Administered SC in Part B, Part C

  • GaretosmabDrug

    Administered IV in Part B

  • SemaglutideDrug

    Administered SC in Part B and Part C

  • Matching Placebo-Part ADrug

    Administered IV or SC in Part A

  • Matching Placebo-TrevogrumabDrug

    Administered SC in Part B and Part C

  • Matching Placebo-GaretosmabDrug

    Administered IV in Part B

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs)Time frame: Baseline to week 7
  2. Severity of TEAEsTime frame: Baseline to week 7
  3. Percent change in total fat massTime frame: Baseline to week 26
  4. Percent change in total lean massTime frame: Baseline to week 26
  5. Percent change in body weightTime frame: Baseline to week 26
  6. Percent change in total fat massTime frame: Baseline to week 52
  7. Percent change in total lean massTime frame: Baseline to week 52
  8. Percent change in body weightTime frame: Baseline to week 52

Locations

60 sites in 2 countries. Site status is shown where the registry gives one.

  • Pinnacle Research Group

    Anniston, Alabama

  • Cullman Clinical Trials

    Cullman, Alabama

  • Foothills Research Center Cct Research

    Phoenix, Arizona

  • Anaheim Clinical Trials

    Anaheim, California

  • ProSciento

    Chula Vista, California

  • Valiance Clinical Research- Huntington Park

    Huntington Park, California

  • Velocity, San Diego

    La Mesa, California

  • Northern California Research

    Sacramento, California

  • Acclaim Clinical Research

    San Diego, California

  • Metabolic Institute of America

    Tarzana, California

  • Valiance Clinical Research

    Tarzana, California

  • Southwest General Healthcare Center

    Fort Myers, Florida

  • Westside Center for Clinical Research

    Jacksonville, Florida

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida

  • IMA Clinical Research St. Petersburg

    St. Petersburg, Florida

  • Precision Clinical Research, LLC

    Sunrise, Florida

  • Clinical Research of West Florida, Inc.

    Tampa, Florida

  • Clinical Research of Central Florida - Bond Clinic

    Winter Haven, Florida

  • Center for Advanced Research and Education

    Gainesville, Georgia

  • Balanced Life Health Care Solutions

    Lawrenceville, Georgia

  • North Georgia Clinical Research

    Woodstock, Georgia

  • East-West Medical Research Institute

    Honolulu, Hawaii

  • Elite Clinical Trials LLLP

    Blackfoot, Idaho

  • Prairie Education and Research Cooperative (PERC)

    Springfield, Illinois

  • The South Bend Clinic Center for Research

    South Bend, Indiana

  • Cotton O'Neil Clinical Research Center

    Topeka, Kansas

  • L-MARC Research Center

    Louisville, Kentucky

  • Tandem Clinical Research GI, LLC

    Marrero, Louisiana

  • IMA Clinical Research Monroe - Armand

    Monroe, Louisiana

  • Mayo Clinic

    Rochester, Minnesota

  • Prime Health and Wellness Clinic

    Fayette, Mississippi

  • Olive Branch Family Medical Center

    Olive Branch, Mississippi

  • Sky Integrative Medical Center Skycrng

    Ridgeland, Mississippi

  • Jefferson City Medical Group

    Jefferson City, Missouri

  • Clinvest Research

    Springfield, Missouri

  • Mercury Street Medical Group, PLLC

    Butte, Montana

  • Hassman Research Institute

    Berlin, New Jersey

  • Accellacare Clinical Research, Raleigh Medical Group

    Raleigh, North Carolina

  • Accellacare of Salisbury

    Salisbury, North Carolina

  • Accellacare of Piedmont, Piedmont Healthcare

    Statesville, North Carolina

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.